Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes
Our study provides a comprehensive evaluation of clinical and economic impacts of therapies administered to patients with mRCC after IO- and VEGF-based therapies. It highlights a need for novel, cost-effective treatments and studies examining patient out-of-pocket costs.
Authors
- Reshma Shinde (ORCID: https://orcid.org/0000-0001-5709-1976)
- Rituparna Bhattacharya (ORCID: https://orcid.org/0000-0002-4505-6994)
- Donna Vickery
- Ning Ning
- Malinda Tan (ORCID: https://orcid.org/0000-0002-0116-0538)
- Jordana K. Schmier (ORCID: https://orcid.org/0000-0002-4662-8800)
- Neil J. Shah (ORCID: https://orcid.org/0000-0001-5752-6212)
- Robert John Motzer (ORCID: https://orcid.org/0000-0001-6925-2327)
- Rodolfo F. Perini (ORCID: https://orcid.org/0009-0002-4400-5260)
- Traci LeMasters (ORCID: https://orcid.org/0000-0002-6998-2650)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Open Society Foundations (US)
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1200/op-25-00278
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52